314 related articles for article (PubMed ID: 24524666)
21. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.
McElroy S; Sachse C; Brockmoller J; Richmond J; Lira M; Friedman D; Roots I; Silber BM; Milos PM
AAPS PharmSci; 2000; 2(4):E33. PubMed ID: 11741249
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.
Pułczyńska A; Łukaszkiewicz J; Wojnar M; Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
Acta Pol Pharm; 2011; 68(1):9-13. PubMed ID: 21485696
[TBL] [Abstract][Full Text] [Related]
23. Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.
Deneer VH; van Schaik RH
Methods Mol Biol; 2013; 1015():345-54. PubMed ID: 23824868
[TBL] [Abstract][Full Text] [Related]
24. A Review of the Important Role of
Taylor C; Crosby I; Yip V; Maguire P; Pirmohamed M; Turner RM
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33143137
[TBL] [Abstract][Full Text] [Related]
25. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Ingelman-Sundberg M
Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
[TBL] [Abstract][Full Text] [Related]
27. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
28. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
29. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.
Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y
Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
31. Accurate determination of the CYP2D6 (*1/*4)xN genotype by quantitative PCR.
Pondman KM; van Schaik RHN; van der Weide J
Drug Metab Pers Ther; 2018 Mar; 33(1):33-39. PubMed ID: 29420304
[TBL] [Abstract][Full Text] [Related]
32. Clinical Utility and Economic Impact of CYP2D6 Genotyping.
Reynolds KK; McNally BA; Linder MW
Clin Lab Med; 2016 Sep; 36(3):525-42. PubMed ID: 27514466
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
Ur Rasheed MS; Mishra AK; Singh MP
Neurochem Res; 2017 Dec; 42(12):3353-3361. PubMed ID: 28871472
[TBL] [Abstract][Full Text] [Related]
34. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
35. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
36. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
[TBL] [Abstract][Full Text] [Related]
37. Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.
Wendt FR; Sajantila A; Moura-Neto RS; Woerner AE; Budowle B
Int J Legal Med; 2018 Jul; 132(4):1007-1024. PubMed ID: 29075918
[TBL] [Abstract][Full Text] [Related]
38. Transfer learning enables prediction of CYP2D6 haplotype function.
McInnes G; Dalton R; Sangkuhl K; Whirl-Carrillo M; Lee SB; Tsao PS; Gaedigk A; Altman RB; Woodahl EL
PLoS Comput Biol; 2020 Nov; 16(11):e1008399. PubMed ID: 33137098
[TBL] [Abstract][Full Text] [Related]
39. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
40. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]